Argos’ eight directors possess extensive experience in science and medicine, industry, and venture capital, providing strategic direction to the Company.


  Audit Nominating and Governance Compensation
Hubert Birner Ph.D., M.B.A.

Hubert Birner Ph.D., M.B.A.
Chairman of the Board

Hubert Birner, Ph.D. has served as the Chairman of our board of directors since 2005 and a member of our board of directors since 2001. Dr. Birner joined the Munich office of TVM Capital, a venture capital firm and affiliate of Argos, as an investment manager in 2000 and currently serves as the Managing Partner of the firm. From 1998 to 2000, Dr. Birner served as head of European business development and director of marketing for Germany at Zeneca Agrochemicals, a biopharmaceutical company. Prior to joining Zeneca Agrochemicals, Dr. Birner served as a management consultant in McKinsey & Company's European healthcare and pharmaceutical practice. Dr. Birner currently serves on the board of directors of Proteon Therapeutics, Inc. and SpePharm Holdings BV. Dr. Birner previously served on the board of directors of Horizon Pharma, Inc., Bioxell SA, Evotec AG and Jerini AG. Dr. Birner received an M.B.A. from Harvard Business School and a doctorate in biochemistry from Ludwig-Maximilians University in Munich, Germany. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases.

 
Robert F. Carey

Robert F. Carey
Director

Robert Carey has been a member of the board of directors since September 2015. Mr. Carey is Executive Vice President and Chief Business officer at Horizon Pharma plc. From 2003 to 2014, Mr. Carey was Managing Director and head of healthcare investment banking at JMP Securities LLC. Prior to that, Mr. Carey held various senior positions at several investment banking firms, including Dresdner Kleinwort Wasserstein, Inc., Prudential Securities Incorporated, Vector Securities International, Inc., and Shearson Lehman Hutton Inc. He has served as an advisor on greater than $15 billion in financings, as well as numerous mergers and acquisitions. He is a member of the board of directors for Red Hen Corporation, Hawthorne Race Course, Inc., and Suburban Downs, Inc. He is also a former member of the board of directors for the Illinois Biotechnology Industry Organization (iBIO). Mr. Carey holds a BBA in accounting from the University of Notre Dame.

   
Andrei Petrov Ph.D.

Andrei Petrov Ph.D.
Director

Andrei Petrov, Ph.D. has served as a member of our board of directors since August 2013. Dr. Petrov has been the Chief Scientific Officer of International Biotechnology Center Generium, a private scientific research and drug development company, since 2011, and the Chief Executive Officer of CJSC 'Kollectsiya,' a venture investment company, since 2013. From 2008 to 2011, Dr. Petrov served as Senior Scientist at CJSC Masterclone, a drug discovery and development company. Dr. Petrov has also served as a member on the board of directors of Affitech A/S since 2010, and as a member on the board of directors of co.don AG since 2012.

 
Brian J. Underdown Ph.D.

Brian J. Underdown Ph.D.
Director

Brian J. Underdown, Ph.D. has served as a member of our board of directors since 1999. Dr. Underdown joined Lumira Capital Corp. (formerly MDS Capital Corp.), a venture capital firm, in 1997, and currently serves as a Managing Director. Before joining Lumira, Dr. Underdown served as Assistant Vice President of Research at Pasteur Merieux Connaught from 1994 to 1997. Dr. Underdown has been a member of the board of directors of Vistagen Therapeutics, Inc. since 2009. Dr. Underdown received a Ph.D. from McGill University and undertook post-doctoral studies at Washington University School of Medicine.

 
Philippe Van Holle M.B.A

Philippe Van Holle M.B.A
Director

Philippe Van Holle, M.B.A. has served as a member of our board of directors since November 2014. He has more than three decades of marketing and sales experience in the pharmaceutical and biotechnology industries with a focus on product life cycle planning, resource deployment, and business and financial planning. From 2006-2014, Mr. Van Holle held multiple positions at Celgene Corporation including Chairman of International, President of EMEA, Head of Europe and, most recently, Senior Vice President of Human Resources. From 2000-2005, Mr. Van Holle served as Vice President at Genzyme in Northern Europe. He has also served as Executive Vice President of Planning at Pharming N.V., Vice President of Global Marketing at Baxter International, and Director of Marketing New Products and Vice President of Marketing at Amgen, Inc. Mr. Van Holle holds an M.B.A. from Cornell University.

 
= Chair of the Board    = Chair    = Member    = Independent Director

Quick Links